Momentum Life Sciences Announces Strategic Growth Investment from Parthenon Capital
Investment Accelerates Company’s Mission to Build the Leading Commercialization Platform Addressing Specialty Therapy Access and Adherence Challenges
Momentum Life Sciences (“Momentum” or the “Company”), a leading commercialization platform offering patient- and provider-facing solutions that support initiation and adherence for specialty therapies, announced a strategic investment from Parthenon Capital, a growth-oriented private equity firm with a long history of supporting innovative companies in healthcare solutions and technology. Following the investment, Momentum’s existing leadership team will continue as significant shareholders in the Company.
The investment will provide Momentum with strategic resources and capital to accelerate its growth strategy and pursue strategic acquisitions that support the Company’s mission to address one of the most persistent challenges facing pharmaceutical and biotechnology manufacturers, patients, and providers: enabling patients to start and stay on the specialty therapies they need.
“This is a defining moment for Momentum and the clients, patients, and providers we serve,” said Andi Heslin Smiley, President and CEO of Momentum Life Sciences. “Partnering with Parthenon provides us with additional resources and an aligned strategic partner to continue to strengthen our platform, deepen our capabilities, and take on a greater role in creating better experiences and outcomes for clients, patients, and providers, which sits at the heart of everything we do.”
